stocks logo

CYTK

Cytokinetics Inc
$
36.630
-0.55(-1.479%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
37.550
Open
37.390
VWAP
--
Vol
863.05K
Mkt Cap
4.37B
Low
36.600
Amount
--
EV/EBITDA(TTM)
--
Total Shares
104.85M
EV
4.16B
EV/OCF(TTM)
--
P/S(TTM)
224.20
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
13.71M
-18.98%
--
--
5.42M
+1070.5%
--
--
1.95M
+682.66%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Cytokinetics, Incorporated (CYTK) for FY2025, with the revenue forecasts being adjusted by -33.81% over the past three months. During the same period, the stock price has changed by -11.14%.
Revenue Estimates for FY2025
Revise Downward
down Image
-33.81%
In Past 3 Month
Stock Price
Go Down
down Image
-11.14%
In Past 3 Month
16 Analyst Rating
up Image
104.12% Upside
Wall Street analysts forecast CYTK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYTK is 74.77 USD with a low forecast of 41.00 USD and a high forecast of 120.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Buy
2 Hold
0 Sell
Strong Buy
up Image
104.12% Upside
Current: 36.630
sliders
Low
41.00
Averages
74.77
High
120.00
JPMorgan
Tessa Romero
Overweight
downgrade
$71 -> $53
2025-06-09
Reason
Mizuho
Salim Syed
Outperform -> Outperform
downgrade
$103 -> $84
2025-05-29
Reason
Mizuho analyst Salim Syed lowered the firm's price target on Cytokinetics to $84 from $103 and keeps an Outperform rating on the shares. The firm updated the company's model post the Q1 report.
Barclays
Overweight
downgrade
$55 -> $53
2025-05-08
Reason
Barclays lowered the firm's price target on Cytokinetics to $53 from $55 and keeps an Overweight rating on the shares following the Q1 report.
Barclays
Gena Wang
Overweight
initiated
$55
2025-04-24
Reason
Barclays analyst Gena Wang initiated coverage of Cytokinetics with an Overweight rating and $55 price target. The firm says the company has a "differentiated" cardiac myosin inhibitor in hypertrophic cardiomyopathy. The analyst sees a high probability of approval for Cytokinetics' lead asset aficamten by the FDA action date of September 26 in obstructive hypertrophic cardiomyopathy. Barclays expects the commercial launch to surpass Camzyos' initial growth trajectory.
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$120
2025-04-21
Reason
B of A Securities
Jason Zemansky
Hold
Maintains
$62 → $54
2025-04-15
Reason

Valuation Metrics

The current forward P/E ratio for Cytokinetics Inc (CYTK.O) is -6.89, compared to its 5-year average forward P/E of -9.84. For a more detailed relative valuation and DCF analysis to assess Cytokinetics Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-9.84
Current PE
-6.89
Overvalued PE
-7.45
Undervalued PE
-12.23

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-9.50
Current EV/EBITDA
-6.71
Overvalued EV/EBITDA
-6.88
Undervalued EV/EBITDA
-12.11

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
179.76
Current PS
81.44
Overvalued PS
378.26
Undervalued PS
-18.74

Financials

Annual
Quarterly
FY2025Q1
YoY :
+89.10%
1.58M
Total Revenue
FY2025Q1
YoY :
+23.29%
-155.63M
Operating Profit
FY2025Q1
YoY :
+18.97%
-161.38M
Net Income after Tax
FY2025Q1
YoY :
+2.26%
-1.36
EPS - Diluted
FY2025Q1
YoY :
+6.00%
-137.28M
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
-81.17%
-2.12K
FCF Margin - %
FY2025Q1
YoY :
-37.09%
-10.22K
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
1.8M
USD
15
3-6
Months
9.4M
USD
26
6-9
Months
1.9M
USD
9
0-12
Months
4.9M
USD
14
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 5964.05% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
880.5K
Volume
2
6-9
Months
14.5K
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
3
1.7M
Volume
Months
6-9
5
3.8M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

CYTK News & Events

Events Timeline

2025-05-13 (ET)
2025-05-13
07:43:28
Cytokinetics announces results from MAPLE-HCM, met primary endpoint
select
2025-05-06 (ET)
2025-05-06
16:05:26
Cytokinetics reports Q1 EPS ($1.36), consensus ($1.36)
select
2025-05-01 (ET)
2025-05-01
17:05:37
Cytokinetics announces PDUFA action date for aficamten
select
Sign Up For More Events

News

4.0
07-06Yahoo Finance
Piper Sandler Maintains a Buy Rating on Cytokinetics (CYTK) With a $107 PT
8.0
06-20NASDAQ.COM
First Week of February 2026 Options Trading For Cytokinetics (CYTK)
8.0
06-12NASDAQ.COM
Noteworthy Thursday Option Activity: CYTK, GOOG, HOFT
Sign Up For More News

FAQ

arrow icon

What is Cytokinetics Inc (CYTK) stock price today?

The current price of CYTK is 36.63 USD — it has decreased -1.48 % in the last trading day.

arrow icon

What is Cytokinetics Inc (CYTK)'s business?

arrow icon

What is the price predicton of CYTK Stock?

arrow icon

What is Cytokinetics Inc (CYTK)'s revenue for the last quarter?

arrow icon

What is Cytokinetics Inc (CYTK)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Cytokinetics Inc (CYTK)'s fundamentals?

arrow icon

How many employees does Cytokinetics Inc (CYTK). have?

arrow icon

What is Cytokinetics Inc (CYTK) market cap?